In this piece, we will look at the stocks Jim Cramer recently discussed.

A roundup of recent health-related developments includes Adani's partnership with Mayo Clinic for affordable healthcare in ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.

Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...

Wall Street rebounds as tech stocks surge, with the S&P 500 up 0.5% amid easing trade tensions and strong corporate earnings.

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...